# OnCo record ependymoma-molecular-groups (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/ependymoma-molecular-groups/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "ependymoma-molecular-groups" ;
  schema:name "Ependymoma molecular groups (PF-A, PF-B, ZFTA, YAP1, MYCN)"@en ;
  schema:alternateName "PF-A"@en, "PFA ependymoma"@en, "posterior fossa group A"@en, "PF-B"@en, "PFB ependymoma"@en, "posterior fossa group B"@en, "ZFTA fusion"@en, "ZFTA::RELA"@en, "RELA fusion"@en, "C11orf95-RELA"@en, "YAP1 fusion"@en, "YAP1::MAMLD1"@en, "supratentorial ependymoma ZFTA fusion-positive"@en, "MYCN-amplified spinal ependymoma"@en, "EZHIP"@en, "H3K27me3 loss in ependymoma"@en, "1q gain ependymoma"@en, "chromosome 1q gain"@en, "6q loss"@en ;
  schema:description "Ependymomas are now named by where they arise and their molecular group: posterior fossa group A (young children, hardest to cure, worse still with 1q gain), group B (older patients, mostly cured with surgery and radiotherapy), supratentorial ZFTA-fusion and YAP1-fusion tumours, and a rare aggressive MYCN-amplified spinal type; the group sets the intensity of radiotherapy and the follow-up."@en ;
  schema:url <https://onco.cc/terms/ependymoma-molecular-groups/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  onco:related <https://onco.cc/technologies/cns-tumour-methylation-classifier/>, <https://onco.cc/terms/h3k27m/>, <https://onco.cc/terms/mycn-amplification/>, <https://onco.cc/terms/extent-of-resection/>, <https://onco.cc/terms/fish/>, <https://onco.cc/terms/radiotherapy/>, <https://onco.cc/terms/cdkn2a-homozygous-deletion/> ;
  onco:cancers <https://onco.cc/cancers/ependymoma/>, <https://onco.cc/cancers/spinal-cord-tumours/> .